passages: 422
passages: document
passages: Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol . PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol . METHODS This was a 6-week , double-masked , randomised multi-centre study . 53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy were recruited . After a run-in period of at least 2 weeks on timolol , 5 mg/ml twice daily , patients were randomised to one of three groups . One group continued on timolol , one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to timolol . The efficacy was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment . RESULTS IOP at baseline and after 6 weeks of treatment ( mean +/- SEM ) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg ( n = 16 ) for patients continuing on timolol , 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg ( n = 17 ) for patients switching to latanoprost , and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg ( n = 17 ) for patients with combined treatment . Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % . CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .
entities: 423
entities: Intervention_Pharmacological
entities: timolol
entities: 424
entities: Intervention_Pharmacological
entities: latanoprost
entities: 425
entities: Intervention_Pharmacological
entities: latanoprost
entities: 426
entities: Intervention_Pharmacological
entities: timolol
entities: 427
entities: Intervention_Pharmacological
entities: timolol
entities: 428
entities: Intervention_Pharmacological
entities: timolol
entities: 429
entities: Intervention_Pharmacological
entities: timolol
entities: 430
entities: Intervention_Pharmacological
entities: latanoprost
entities: 431
entities: Intervention_Pharmacological
entities: latanoprost
entities: 432
entities: Intervention_Pharmacological
entities: timolol .
entities: 433
entities: Outcome_Physical
entities: IOP-reducing
entities: 434
entities: Outcome_Physical
entities: intraocular pressure ( IOP )
entities: 435
entities: Outcome_Physical
entities: IOP
entities: 436
entities: Outcome_Physical
entities: IOP
entities: 437
entities: Outcome_Physical
entities: IOP
entities: 438
entities: Outcome_Physical
entities: IOP
entities: 439
entities: Outcome_Physical
entities: IOP
entities: 440
entities: Outcome_Physical
entities: IOP
entities: 441
entities: Participant_Condition
entities: patients insufficiently controlled on timolol .
entities: 442
entities: Participant_Condition
entities: patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .
entities: 443
entities: Participant_Sample-size
entities: 53
entities: 444
entities: Participant_Condition
entities: patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy